Humanigen, Cenexi Ink Manufacture Pact For COVID-19 Candidate, Lenzilumab, In France

Humanigen Inc HGEN has selected Cenexi as a preferred supplier of lenzilumab in France and the European Union. 

• Cenexi is a French CDMO specializing in the formulation, analytical development, and manufacture of complex molecule drugs.
• The initial step of the collaboration includes executing a Master Supply Agreement providing for Cenexi to provide aseptic fill and finish services for lenzilumab for the next five years.
• Humanigen plans to include the Cenexi's Normandy site in certain of its future regulatory filings for lenzilumab for COVID-19 and other indications.
• Related: After FDA Rejection, Humanigen's COVID-19 Drug Hopeful Sees Some Light Of Good News.
• The companies will collaborate to secure potential funding and investment in capital equipment from AD Normandie, the regional authority, and the Government of France, the national authority. 
• In addition, Cenexi will assist Humanigen as it seeks an advanced purchase agreement for lenzilumab in France.
• Humanigen is developing lenzilumab to treat cytokine storm associated with COVID-19 and CD19-targeted CAR-T cell therapies.
• It is also exploring lenzilumab in other inflammatory conditions such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation, eosinophilic asthma, and rheumatoid arthritis. 
• Price Action: HGEN shares are down 0.25% at $2.01 during the market session on the last check Wednesday.